Compare Boston Scientific Corporation (BSX) vs Electronic Arts Inc. (EA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Electronic Arts Inc. — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while Electronic Arts Inc. trades at $206.65 (market cap $51.82B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Electronic Arts Inc. pays a 0.37% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | EA | |
|---|---|---|
Market Cap | $66.37B | $51.82B |
Sector | Health | Technology |
52-Week High | $108.14 | $206.65 |
52-Week Low | $42.63 | $147.79 |
Enterprise Value | $75.94B | $50.39B |
Dividend Yield | — | 0.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Electronic Arts (EA) trades at $206.35, down 0.03% on the day, with a bullish technical signal from moving averages and mixed earnings performance including a recent Q4 2025 beat. The company maintains strong profitability with a 78.97% gross margin and 11.78% net margin, though valuation ratios like P/E of 58.79 appear elevated. Recent launches of EA SPORTS College Football 27 and UFC 6, plus the new EA Advertising platform, highlight ongoing growth initiatives.
Outlook is cautiously optimistic given analyst consensus leaning Hold (56.06%) versus Buy (43.94%), with risks including earnings volatility and high valuation. The potential $55 billion acquisition by Saudi investors, pending EU approval, could significantly impact shareholder value, while consistent cash flow from operations supports dividend stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →
